Childhood-onset severe hypereosinophilic asthma: efficacy of benralizumab

Severe hypereosinophilic asthma in children is extremely rare. This letter adds to the existing literature by providing long-term follow-up, and is the first report of the marked efficacy of benralizumab after failure of other biologic treatments. https://bit.ly/2G7Tc2k

Detalles Bibliográficos
Autores principales: Just, Jocelyne, Bourgoin, Melisande, Amat, Flore, Cottel, Nathalie, Lambert, Nathalie, Wanin, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Original Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792776/
https://www.ncbi.nlm.nih.gov/pubmed/33447610
http://dx.doi.org/10.1183/23120541.00339-2020
Descripción
Sumario:Severe hypereosinophilic asthma in children is extremely rare. This letter adds to the existing literature by providing long-term follow-up, and is the first report of the marked efficacy of benralizumab after failure of other biologic treatments. https://bit.ly/2G7Tc2k

Ejemplares similares